Ư¹ß¼º Æó¼¶À¯Áõ Áø´Ü ¹× Ä¡·á ½ÃÀå : ¿¹Ãø(2025-2030³â)
Idiopathic Pulmonary Fibrosis Diagnostic And Treatment Market - Forecasts from 2025 to 2030
»óǰÄÚµå : 1775524
¸®¼­Ä¡»ç : Knowledge Sourcing Intelligence
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 144 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,950 £Ü 5,563,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,550 £Ü 6,408,000
PDF (Multiple User License) help
PDF º¸°í¼­¸¦ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,789,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Ư¹ß¼º Æó¼¶À¯Áõ Áø´Ü ¹× Ä¡·á ½ÃÀåÀº CAGR 7.64%·Î, 2025³â 59¾ï 1,700¸¸ ´Þ·¯¿¡¼­ 2030³â¿¡´Â 85¾ï 4,900¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ º¸°í¼­´Â ¼¼°è Ư¹ß¼º Æó¼¶À¯Áõ(IPF) Áø´Ü ¹× Ä¡·á ½ÃÀåÀ» Á¾ÇÕÀûÀ¸·Î ºÐ¼®ÇÏ¿© ÀÌ Áß¿äÇÑ ÇコÄÉ¾î ºÐ¾ß¸¦ Çü¼ºÇÏ´Â ½ÃÀå µ¿Çâ, Ä¡·á ¹ßÀü ¹× °æÀï Àü·«¿¡ ´ëÇØ ¾÷°è Àü¹®°¡µé¿¡°Ô Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. º» º¸°í¼­¿¡¼­´Â À¯Çüº°, ¾à¹° À¯Çüº°, Åõ¿© °æ·Îº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°·Î ¼¼ºÐÈ­ÇÏ¿© ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ½ÃÀå ±âȸ µî ÁÖ¿ä ½ÃÀå ¿ªÇп¡ ´ëÇØ Á¶»çÇÏ¿´½À´Ï´Ù. º» ½ÃÀå ÇöȲ Á¶»ç´Â Àü·«Àû ÀÇ»ç°áÁ¤À» Áö¿øÇϱâ À§ÇÑ °ÍÀ¸·Î, ÀÌÇØ°ü°èÀڵ鿡°Ô IPF ¼Ö·ç¼ÇÀÇ ÁøÈ­ÇÏ´Â »óȲÀ» Ž»öÇÒ ¼ö ÀÖ´Â µ¥ÀÌÅÍ ±â¹Ý ¿¹Ãø, ±ÔÁ¦ ȯ°æ, °æÀï Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

Á¶»ç °³¿ä

Ư¹ß¼º Æó¼¶À¯Áõ(IPF) Áø´Ü ¹× Ä¡·á ½ÃÀå Á¶»ç º¸°í¼­´Â ¼¼°è IPF ½ÃÀåÀ» À¯Çüº°(Áø´Ü °Ë»ç, ¾à¸®ÇÐÀû ¾à¹°, Ä¡·á), ¾à¹° À¯Çüº°(ÇǸ£Æä´Ïµ·, ´ÑÅ×´Ù´Õ, ±âŸ), Åõ¿© °æ·Îº°(°æ±¸, ºñ°æ±¸), ÃÖÁ¾ ¿ëµµº°(º´¿ø ¹× Ŭ¸®´Ð, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ, ±âŸ), Áö¿ªº°(ºÏ¹Ì, ³²¹Ì, À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«, ¾Æ½Ã¾ÆÅÂÆò¾ç)À¸·Î ºÐ·ùÇÏ¿© Á¶»çÇϰí ÀÖ½À´Ï´Ù. Porter's Five Forces ºÐ¼®, »ê¾÷ ¹ë·ùüÀÎ ºÐ¼®, ½ÃÀå Á¡À¯À² Æò°¡ µî źźÇÑ ºÐ¼®°ú ÇÔ²² Àü·«Àû Á¦¾È ¹× ±ÔÁ¦¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÏ¿© ÀÌÇØ°ü°èÀÚµéÀÌ ÀÌ Áß¿äÇÑ ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ Ȱ¿ëÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

°æÀï ȯ°æ ¹× ºÐ¼®

Ư¹ß¼º Æó¼¶À¯Áõ Áø´Ü ¹× Ä¡·á ½ÃÀå Á¶»çÀÇ °æÀï Á¤º¸ ¼½¼Ç¿¡¼­´Â ÁÖ¿ä ±â¾÷µéÀÌ ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­Çϱâ À§ÇÑ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê¸¦ °­Á¶Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, º£¸µ°ÅÀΰÖÇÏÀÓÀº ÃÖ±Ù ÀûÀÀÁõ È®´ë¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ» ¹ÞÀ½À¸·Î½á ´ÑÅ×´Ù´Õ-Æ÷ÅäÆú¸®¿À¸¦ ¹ßÀü½ÃÄÑ º´¿ø ¹× Ŭ¸®´Ð¿¡¼­ IPF Ä¡·á¿¡ ´ëÇÑ Àû¿ëÀ» °­È­Çß½À´Ï´Ù. À̹ø °³¹ßÀº ¾à¸®ÇÐÀû ¼Ö·ç¼Ç ºÐ¾ß¿¡¼­ º£¸µ°ÅÀΰÖÇÏÀÓÀÇ ¸®´õ½ÊÀ» °­È­ÇÏ´Â °è±â°¡ µÉ °ÍÀÔ´Ï´Ù. ¸¶Âù°¡Áö·Î ÆÄÀ̺ê·ÎÁ¨Àº IPF Á¶±â ¹ß°ßÀ» À§ÇÑ »õ·Î¿î Áø´Ü °Ë»ç¹ý °³¹ßÀ» À§ÇÑ Àü·«Àû Á¦ÈÞ¸¦ ÅëÇØ ÀÓ»ó ÆÄÀÌÇÁ¶óÀÎÀ» ¹ßÀü½ÃÄÑ ÇコÄÉ¾î ºÐ¾ß¿¡¼­ ȯÀÚ ¿¹Èĸ¦ °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. º» Á¶»ç¿¡¼­´Â ½ÃÀå Á¡À¯À² ºÐ¼®, ÀμöÇÕº´, °æÀï »óȲÀ» Àü¹ÝÀûÀ¸·Î ÆÄ¾ÇÇÒ ¼ö ÀÖ´Â °æÀï ´ë½Ãº¸µåµµ ÇÔ²² ´Ù·ç°í ÀÖ½À´Ï´Ù.

°á·Ð

ÀÌ Á¶»ç º¸°í¼­´Â IPF Áø´Ü ¹× Ä¡·á ½ÃÀåÀÇ º¹À⼺À» ÀÌÇØÇϰíÀÚ ÇÏ´Â ¾÷°è Àü¹®°¡¿¡°Ô ÇʼöÀûÀÎ ÀÚ·áÀÔ´Ï´Ù. »ó¼¼ÇÑ ¼¼ºÐÈ­, ±â¼ú Àü¸Á, °æÀï Á¤º¸¸¦ Á¦°øÇÔÀ¸·Î½á ÀÌ Á¶»ç´Â ±âȸ¸¦ ½Äº°Çϰí È¿°úÀûÀÎ Àü·«À» ¼ö¸³ÇÒ ¼ö ÀÖ´Â °ß°íÇÑ ÇÁ·¹ÀÓ¿öÅ©¸¦ Á¦°øÇÕ´Ï´Ù. Boehringer Ingelheim, FibroGen, Inc. µîÀÇ ÁÖ¿ä ±â¾÷µéÀÌ ¾à¸®ÇÐ ¹× Áø´Ü ºÐ¾ßÀÇ Çõ½ÅÀ» ÁÖµµÇϰí ÀÖ´Â °¡¿îµ¥, ÀÌ ½ÃÀå Á¶»ç´Â ÀÌÇØ°ü°èÀÚµéÀÌ ¿ªµ¿ÀûÀÌ°í ºü¸£°Ô ÁøÈ­ÇÏ´Â ÀÌ »ê¾÷¿¡¼­ °æÀï·ÂÀ» À¯ÁöÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. °æÀï·ÂÀ» À¯ÁöÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù.

º» º¸°í¼­ÀÇ ÁÖ¿ä ÀåÁ¡

¾î¶² ¿ëµµ·Î »ç¿ëµÇ´Â°¡?

»ê¾÷ ¹× ½ÃÀå ÀλçÀÌÆ®, »ç¾÷ ±âȸ Æò°¡, Á¦Ç° ¼ö¿ä ¿¹Ãø, ½ÃÀå ÁøÀÔ Àü·«, Áö¸®Àû È®Àå, ¼³ºñ ÅõÀÚ °áÁ¤, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ© ¹× ¿µÇâ, ½ÅÁ¦Ç° °³¹ß, °æÀïÀÇ ¿µÇâ

Á¶»ç ¹üÀ§

Ư¹ß¼º Æó¼¶À¯Áõ Áø´Ü ¹× Ä¡·á ½ÃÀå º¸°í¼­°¡ ´Ù·ç´Â ´Ù¾çÇÑ ºÎ¹®Àº ´ÙÀ½°ú °°½À´Ï´Ù:

À¯Çüº°

¾àÁ¦ Á¾·ùº°

Åõ¿© °æ·Îº°

¿ëµµº°

Áö¿ªº°

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå ÇöȲ

Á¦3Àå ºñÁî´Ï½º »óȲ

Á¦4Àå ±â¼ú Àü¸Á

Á¦5Àå Æ¯¹ß¼º Æó¼¶À¯Áõ Áø´Ü ¹× Ä¡·á ½ÃÀå : À¯Çüº°

Á¦6Àå Æ¯¹ß¼º Æó¼¶À¯Áõ Áø´Ü ¹× Ä¡·á ½ÃÀå : ¾à¹° À¯Çüº°

Á¦7Àå Æ¯¹ß¼º Æó¼¶À¯Áõ Áø´Ü ¹× Ä¡·á ½ÃÀå : Åõ¿© °æ·Îº°

Á¦8Àå Æ¯¹ß¼º Æó¼¶À¯Áõ Áø´Ü ¹× Ä¡·á ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

Á¦9Àå Æ¯¹ß¼º Æó¼¶À¯Áõ Áø´Ü ¹× Ä¡·á ½ÃÀå : Áö¿ªº°

Á¦10Àå °æÀï ȯ°æ°ú ºÐ¼®

Á¦11Àå ±â¾÷ °³¿ä

Á¦12Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Idiopathic Pulmonary Fibrosis Diagnostic And Treatment Market is expected to grow from USD 5.917 billion in 2025 to USD 8.549 billion in 2030, at a CAGR of 7.64%.

The Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Study provides a comprehensive analysis of the global idiopathic pulmonary fibrosis (IPF) diagnostic and treatment market, offering industry experts critical insights into market trends, therapeutic advancements, and competitive strategies shaping this vital healthcare sector. This study explores key market dynamics, including drivers, restraints, and opportunities, with detailed segmentation by type, drug type, route of administration, end-use, and geography. Designed to support strategic decision-making, the Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Study equips stakeholders with data-driven forecasts, regulatory insights, and competitive intelligence to navigate the evolving landscape of IPF solutions.

Study Overview

The Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Study examines the global IPF market, segmented by type (Diagnostic Testing, Pharmacological Drugs, Surgical Treatment), drug type (Pirfenidone, Nintedanib, Others), route of administration (Oral, Parenteral), end-use (Hospitals and Clinics, Ambulatory Surgical Centers, Others), and geography (North America, South America, Europe, Middle East and Africa, Asia Pacific). It includes robust analyses such as Porter's Five Forces Analysis, Industry Value Chain Analysis, and market share evaluations, alongside strategic recommendations and regulatory insights to help stakeholders capitalize on growth opportunities in this critical market.

Competitive Environment and Analysis

In the competitive intelligence section of the Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Study, key players are highlighted for their strategic initiatives to strengthen market presence. For instance, Boehringer Ingelheim has recently advanced its nintedanib portfolio by securing regulatory approvals for expanded indications, enhancing its application in IPF treatment across hospitals and clinics. This development reinforces Boehringer Ingelheim's leadership in pharmacological solutions. Similarly, FibroGen, Inc. has progressed its clinical pipeline through a strategic collaboration to develop novel diagnostic testing methods for early IPF detection, targeting improved patient outcomes in the healthcare sector. The study also covers market share analysis, mergers, acquisitions, and a competitive dashboard to provide a holistic view of the competitive landscape.

Conclusion

The Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Study is an essential resource for industry experts seeking to understand the complexities of the IPF diagnostic and treatment market. By offering detailed segmentation, technological outlooks, and competitive intelligence, this study provides a robust framework for identifying opportunities and formulating effective strategies. With leading players like Boehringer Ingelheim and FibroGen, Inc. driving innovation in pharmacological and diagnostic advancements, the Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Study empowers stakeholders to stay competitive in this dynamic and rapidly evolving industry.

Key Benefits of this Report:

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Different segments covered under the idiopathic pulmonary fibrosis diagnostic and treatment market report are as below:

By Type

By Drug Type

By Route of Administration

BY End-Use

By Geography

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

3. BUSINESS LANDSCAPE

4. TECHNOLOGICAL OUTLOOK

5. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY TYPE

6. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY DRUG TYPE

7. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY ROUTE OF ADMINISTRATION

8. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY END-USE

9. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY GEOGRAPHY

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

11. COMPANY PROFILES

12. APPENDIX

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â